ETF Holdings Breakdown of AXSM

News associated with AXSM

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $162.00

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price lifted by Robert W. Baird from $160.00 to $162.00 in a report released on Tuesday, Marketbeat reports. Robert W. Baird currently has an outperform rating on the stock. Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” […] - 2025-05-09 06:56:43

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,228 shares of the company’s stock after acquiring an additional 3,366 shares during the period. Price T Rowe Associates […] - 2025-05-07 08:50:49

Axsome Therapeutics (NASDAQ:AXSM) Trading Up 5.6% After Earnings Beat

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s stock price was up 5.6% during trading on Monday following a better than expected earnings announcement. The stock traded as high as $117.60 and last traded at $118.54. Approximately 231,459 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 683,737 […] - 2025-05-07 05:24:42

Legal & General Group Plc Decreases Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Legal & General Group Plc cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,370 shares of the company’s stock after selling 503 shares during the period. Legal […] - 2025-04-24 08:06:51

Raymond James Financial Inc. Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Raymond James Financial Inc. bought a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 174,586 shares of the company’s stock, valued at approximately $14,771,000. A number of […] - 2025-04-22 08:10:57

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Summit Investment Advisors Inc.

Summit Investment Advisors Inc. boosted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,852 shares of the company’s stock after purchasing an additional 162 shares […] - 2025-04-21 07:56:55

Russell Investments Group Ltd. Boosts Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Russell Investments Group Ltd. boosted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1,815.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,437 shares of the company’s stock after buying an additional 18,422 shares during the quarter. Russell Investments Group Ltd.’s holdings in Axsome Therapeutics were worth $1,645,000 as of its […] - 2025-04-20 08:20:47

Jefferies Financial Group Initiates Coverage on Axsome Therapeutics (NASDAQ:AXSM)

Jefferies Financial Group started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $200.00 price objective on the stock. AXSM has been the topic of several other reports. William Blair reaffirmed an “outperform” rating […] - 2025-04-08 05:40:49

Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Schroder Investment Management Group decreased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 58.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,142 shares of the company’s stock after selling 34,158 shares during the quarter. Schroder […] - 2025-04-07 08:13:00

Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) PT at $167.64

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received an average rating of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have covered the stock in the […] - 2025-04-03 05:50:59

KLP Kapitalforvaltning AS Makes New $745,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 8,800 shares of the company’s stock, valued at approximately $745,000. Other institutional investors and hedge funds have […] - 2025-04-02 08:12:56

Cibc World Markets Corp Purchases Shares of 3,445 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Cibc World Markets Corp acquired a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,445 shares of the company’s stock, valued at approximately $291,000. A number of other hedge funds and […] - 2025-03-25 08:16:52

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Recommendation of “Buy” from Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has earned a consensus rating of “Buy” from the fifteen ratings firms that are covering the stock, MarketBeat Ratings reports. Fifteen equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock […] - 2025-03-06 07:33:01

Axsome Settles Patent Litigation With Hikma Related To Sunosi - Quick Facts

(RTTNews) - Axsome Therapeutics (AXSM) has entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. resolving patent litigation related to Axsomes product Sunosi or solriamfetol. Axsome will grant Hikma a license to sell its generic version of Sunosi beginning on - 2025-03-05 12:42:10

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Robert W. Baird Analyst Says

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective hoisted by stock analysts at Robert W. Baird from $132.00 to $160.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 27.42% from […] - 2025-03-05 06:32:48

Handelsbanken Fonder AB Sells 500 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Handelsbanken Fonder AB lessened its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,800 shares of the company’s stock after selling 500 shares during the quarter. Handelsbanken Fonder AB’s holdings in […] - 2025-02-28 09:25:09

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Lowered by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D decreased its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.9% during the 4th quarter, HoldingsChannel reports. The firm owned 21,990 shares of the company’s stock after selling 421 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Axsome Therapeutics […] - 2025-02-25 09:20:52

Axsome Therapeutics (NASDAQ:AXSM) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $153.00 target price on the stock. Other analysts also recently issued research reports about the stock. Needham & Company LLC increased their target price on […] - 2025-02-20 09:05:34

Axsome Therapeutics (NASDAQ:AXSM) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Tuesday,RTT News reports. Other equities research analysts have also recently issued reports about the company. Bank of America lifted their price objective on Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” […] - 2025-02-19 08:46:48

Wells Fargo & Company Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target raised by equities research analysts at Wells Fargo & Company from $140.00 to $160.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 21.51% […] - 2025-02-14 09:35:09

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Mizuho Analyst Says

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price raised by research analysts at Mizuho from $137.00 to $195.00 in a report released on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price target suggests a potential upside of 48.23% from the company’s previous close. Other equities analysts […] - 2025-02-13 08:52:53

HC Wainwright Reiterates “Buy” Rating for Axsome Therapeutics (NASDAQ:AXSM)

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $190.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 44.43% from the company’s current price. Several other research […] - 2025-02-13 08:52:48

Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Bank of America Analyst Says

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price boosted by investment analysts at Bank of America from $143.00 to $167.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price suggests a potential upside of […] - 2025-02-13 08:52:47

Deutsche Bank Aktiengesellschaft Begins Coverage on Axsome Therapeutics (NASDAQ:AXSM)

Deutsche Bank Aktiengesellschaft started coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $176.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 33.79% from the stock’s […] - 2025-02-13 08:52:47

Axsome Therapeutics (NASDAQ:AXSM) Receives Buy Rating from Needham & Company LLC

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a research note issued on Monday,Benzinga reports. They presently have a $133.00 price target on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 0.61% from the stock’s previous close. Several […] - 2025-02-12 09:18:43

Axsome Therapeutics (NASDAQ:AXSM) Sets New 52-Week High Following Analyst Upgrade

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday after Bank of America raised their price target on the stock from $143.00 to $167.00. Bank of America currently has a buy rating on the stock. Axsome Therapeutics traded as high as $132.25 and last traded […] - 2025-02-12 06:37:10

Mizuho Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target increased by equities researchers at Mizuho from $122.00 to $137.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target would suggest a potential upside of 21.32% from the company’s previous close. Several […] - 2025-02-05 06:28:49

Axsome Therapeutics (NASDAQ:AXSM) Given New $190.00 Price Target at Truist Financial

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective lifted by analysts at Truist Financial from $180.00 to $190.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price suggests a potential upside of 68.26% from the company’s previous […] - 2025-02-05 06:28:48

AXSM institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	20,570	USD 2,239,250
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,205	USD 675,476 -1.8%
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	47,972	USD 5,222,232 -1.8%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	23,216	USD 2,527,294
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	23,216	USD 2,527,294 -1.8%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	81	USD 8,818 -1.8%
Total =		121,260	USD 13,200,364

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer